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Abstract
Chronic pancreatitis (CP) is an inflammatory disease 
of the pancreas evolving in progressive fibrotic 
disruption of the gland with exocrine and endocrine 
pancreatic insufficiency. Although imaging features 
of CP are well known, their correlation with exocrine 
pancreatic function tests are not obvious, particularly 
in the early stage of the disease. There are many 
clinical classification of CP, all suggested for better 
distinguish and manage different forms based on 
etiological and clinical factors, and severity of the 
disease. Recently, a new classification of CP has 
been suggested: the M-ANNHEIM multiple risk factor 
classification that includes etiology, stage classification 
and degree of clinical severity.  However, more accurate 
determination of clinical severity of CP requires a 
correct determination of exocrine function of the 
pancreas and fecal fat excretion. Recently, Kamath et al 
demonstrated that the evaluation of exocrine pancreatic 
function by acid steatocrit and fecal elastase-1 (EF-1) 
was helpful, but EF-1 was able to detect exocrine 
pancreatic insufficiency in more patients, upgrading 
some patients in higher stage of disease according to 
M-ANNHEIM classification. So, EF-1 is a more accurate 
test to determine exocrine pancreatic insufficiency 
and to stage chronic pancreatitis in the M-ANNHEIM 
classification. On the contrary, EF-1 determination 
shows low sensitivity in detecting exocrine pancreatic 
insufficiency in early stage of the disease.
Key words: Chronic pancreatitis; Exocrine pancreatic 
insufficiency; Fecal elastase-1; Pancreatic function 
tests; Steathorrea
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Core tip: Classification of chronic pancreatitis is useful 
for planning adequate diagnosis and management 
of the disease, particularly in the early detection and 
prevention of related-complications. Recognition of 
pancreatic exocrine insufficiency is useful for graduating 
severity of chronic pancreatitis in modern classification 
systems, and fecal elastase determination appears 
the better method in term of simplicity and sensitivity 
to stage exocrine function of the pancreas. However, 
sensitivity of elastase-1 is low in early stage of chronic 
pancreatitis, and new diagnostic tools or combination 
of different procedures are needed to better stage 
pancreatic function.
Sperti C, Moletta L. Staging chronic pancreatitis with exocrine 
function tests: Are we better? World J Gastroenterol 2017; 
23(38): 6927-6930  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i38/6927.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i38.6927
INTRODUCTION
Chronic pancreatitis (CP) is the most commonly 
known cause of pancreatic exocrine insufficiency 
(PEI)[1].  Every patient with a new diagnosis of CP 
should be screened for PEI and in order to detect 
maldigestion prior to the occurrence of overt clinical 
symptoms, the presence of PEI should be evaluated 
annually in patients with CP. PEI can lead to poor 
quality of life, steathorrea, abdominal pain and 
malabsorption, and early diagnosis of PEI is important 
to prevent malnutrition-related complications. Many 
tests are nowadays available for the diagnosis of 
PEI, but each one has some diagnostic limitations. 
As a consequence, PEI is still underdiagnosed and 
undertreated.  In addition to its clinical relevance, 
PEI represents an helpful method for staging CP in 
different classification systems. The M-ANNHEIM 
classification is a new system for staging and grading 
the severity of CP[2]. The M-ANNHEIM classification 
system is based on the categorization determined by 
etiological factors, clinical stage and severity of CP. 
This system constitutes   a simple, objective, accurate 
and non-invasive method for clinicians which combines 
the influence  and interaction of several risk factos 
on the course of the disease. These multiple (M) risk 
factors included the subsets of alcohol consumption 
(A), nicotin consumption (N), nutritional factors 
(N), hereditary factors (H), efferent pancreatic duct 
factors (E), immunological factors (I), and various 
rare miscellaneous and metabolic (M) factors[2]. 
The M-ANNHEIM staging of CP is divided into an 
asymptomatic phase (stage 0) and a symptomatic 
phase (stages I, II, III, IV) of the disease[2]. The 
latter phase represents the period of clinically evident 
chronic  inflammation of he pancreas. The evaluation 
of the symptomatic phases of CP is based on pain 
and on the presence and degree of PEI[2]. An accurate 
evaluation of PEI is therefore necessary to validate 
the diagnosis and allow the proper treatment of the 
disease. In fact, a correct diagnosis of PEI suggests 
the pancreatic enzyme replacement therapy (PERT) 
and it is essential to monitor the efficacy of treatment 
in order to avoid complications of CP. Only few studies 
in the literature have compared the different diagnostic 
power of the tests available to evaluate PEI, and only 
few data are available for determining their role in the 
present staging system of CP.
STUDY ANALYSIS
In the recent issue of the World Journal of Gastro­
enterology, Kamath et al[3] reported a prospective 
analysis comparing two tests for PEI to use in 
M-ANNHEIM staging for pancreatitis. In this study, 116 
patients with CP were included. PEI was analyzed by 
faecal elastase-1 (FE-1) value and fecal fat excretion 
by the acid steatocrit method. Based on the results of 
the two tests, the patients were separately categorized 
as per M-ANNHEIM stages. Among the 116 patients 
with CP, the presence of PEI was evident in 61 (52.5%) 
and 79 (68.1%) by the acid steatocrit method and 
FE-1, respectively. A statistically significant difference 
was seen between the M-ANNHEIM stages as classified 
separately by acid steatocrit and the FE-1. The Authors 
concluded that FE-1 estimation permits better staging 
of pancreatitis by the M-ANNHEIM classification, 
since it diagnosed a higher number  of patients with 
exocrine pancreatic insufficiency. They recommend 
the use of FE-1 test for staging CP by the M-ANNHEIM 
classification. The study of Kamath et al[3] is interesting 
because it deals with the assessment of PEI, which still 
remains a diagnostic challenge in patients affected by 
CP.
The ideal test for the diagnosis of PEI should be 
accurate, non-invasive, widely available and easy to 
perform.  In our Center, in twenty years of experience, 
we observed 325 patients with a diagnosis of CP, and 
among them 253 received surgery[4,5]. In this period, 
different tests were used to diagnose PEI (fecal fat 
excretion, p-aminobenzoic acid test, coefficient of 
fat absorption, fecal chymotrypsin)[4-6], and in more 
recent years they have been replaced by FE-1 test. 
Nowadays, two different groups of tests (direct and 
indirect tests) are available for the diagnosis of PEI[1] 
(Table 1). Among direct tests, the most sensitive 
method is derived from the aspiration of the pancreatic 
secretions during secretin-cholecystokinin/cerulein 
administration[7]. However, this test is invasive and it 
is available only in few specialized centers[7].  Among 
indirect test, the coefficient of fat absorption (CFA), the 
fecal-elastase-1 determination and the acid steatocrit 
test are the most frequently used[7].  FDA have 
approved treatments for PEI based on randomized 
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controlled trials that used CFA to define PEI[8]. The 
CFA is also useful to monitor pancreatic enzyme 
replacement therapy (PERT). The CFA requires patients 
to maintain a strict diet containing 100 g of fat per 
day over five days, and to collect the total amount of 
stools excreted over the last three days[9]. A CFA < 
93% is considered pathological[9]. However, this test is 
not easy to perform, it is difficult to control the amount 
of fat consumed, especially in alcoholic patients, and 
collection of faeces is unpleasant and cumbersome 
for patients.  Fecal Elastase-1 (FE-1) is an indirect 
assessment of the pancreatic secretion. This test is 
easy to perform, widely available and only requires a 
small stool sample for analysis[10]. However, FE-1 test 
is not able to exclude mild to moderate PEI, and there 
is no consensus concerning the ideal cut-off for PEI 
in patients with CP: figures of < 15, 50, 100 and 200 
mg/g have been proposed, and a threshold of 200 
mg/g has been used most frequently in accordance 
with the intended use label of the test[11]. The acid 
steatocrit method is a quantitative measurement of fat 
expressed as a proportion of an entire centrifugated 
homogenized stool sample; it correlates well with the 
72 h quantitative faecal fat estimation[12].  However, 
the acid steatocrit method has some disadvantages 
which include a lack of standardization of the test 
and the possible effect of dietary fat intake during the 
sample collection[12].
Other tests are currently available. The 13 C-Mixed 
Triglyceride Breath test (TGBT)  is a valid  alternative 
to the CFA, both for the diagnosis of PEI and for 
evaluating the efficacy of PERT in clinical practice[13]. 
Modifications of the test may allow the detection 
of mild to moderate PEI[13]. However, the test also 
has limitations in terms of specificity (false positive 
results in non-pancreatic fat malabsorption), it is not 
easily available since it is commercialized only in few 
European countries. Pancreatic secretion volume can 
be evaluated semiquantitatively by secretin enhanced-
MRCP (s-MRCP)[14]. Pancreatic secretion evaluated 
by this technique correlates with FE-1 test results; 
however, its sensitivity for PEI is as low as 69%[14]. In 
addition, there is very limited evidence supporting this 
technique for the diagnosis of PEI in clinical practice.
In conclusion, many tests are available for the 
diagnosis and evaluation of PEI in CP, but every 
test has some limits and pitfalls. In particular, a 
diagnostic, non-invasive method to differentiate mild 
and moderate PEI is still required. Further studies are 
needed to identify the ideal method in the diagnostic 
setting of PEI.   
PERSPECTIVE
Accurate staging of pancreatitis is crucial to study both 
the natural history of the disease and the effect of 
treatment. In the study by Kalmath et al[3], acid steatocrit 
and FE1 were compared, while other standard tests 
like CFA or the 13 C-Mixed Triglyceride Breath test 
were not considered. It would be interesting in future 
studies to investigate the comparative usefulness of 
these tests comprehensively. Moreover, it is reasonable 
to believe that the additional use of biomarkers could 
improve the staging systems and this aspect should 
be explored in future studies. Recently, it has been 
reported that serum monocyte chemoattractant 
protein-1 levels were lower in patients with CP and 
PEI as compared to patients with CP without PEI[15]. A 
panel of 6 serum miRNA has been recently suggested 
as potential useful investigation for diagnosis of CP, 
especially for the early diagnosis of CP[16]. Future 
studies concerning the association of tests, such as 
pancreatic function tests, biomarkers or radiological-
endoscopic imaging, could be helpful for the early 
detection of CP.
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